| Literature DB >> 35698130 |
Vincent Crenn1,2, Yonis Quinette3, Charlie Bouthors4, Gilles Missenard4, Brice Viard4, Philippe Anract5, Stéphane Boisgard6, Eric Mascard7, François Gouin3,8,9.
Abstract
PURPOSE: Bone healing in femoral reconstructions using intercalary allografts can be compromised in a tumour context. There is also a high revision rate for non-union, infection, and fractures in this context. The advantages and disadvantages of an associated vascularised fibula graft (VFG) are still a matter of debate.Entities:
Keywords: Bone reconstruction; Bone tumour; Intercalary allograft; Vascularised fibula graft
Mesh:
Year: 2022 PMID: 35698130 PMCID: PMC9195446 DOI: 10.1186/s12957-022-02650-x
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 3.253
Fig. 1Vascularised fibula embedded in the femoral allograft before implantation. The allograft window allows vascular anastomosis according to the Capanna technique [15]
Fig. 2Study flowchart
Description of the population of the entire cohort and comparison of the qualitative data between the VFG+ and VFG− subgroups using the chi2 or Fisher’s exact test and for the quantitative data the t-test
| Cohort, | VFG+, | VFG−, | ||
|---|---|---|---|---|
| Age (years) | 20.9 (7–62) | 19.6 (7–48) | 21.7 (9–62) | 0.553 |
| Male | 16 (34.8%) | 8 (44.4%) | 8 (28.6%) | 0.270 |
| Female | 30 (65.2%) | 10 (55.6%) | 20 (71.4%) | |
| Follow-up (months) | 132.7 (24–402) | 114.9 (37–233) | 145.8 (24–402) | 0.250 |
| Resection length (mm) | 198 (100–340) | 190 (140–260) | 203 (100–300) | 0.395 |
| 0.088 | ||||
| Osteosarcoma | 26 (56.5%) | 9 (50.0%) | 17 (60.7%) | |
| Ewing’s sarcoma | 11 (23.9%) | 7 (38.9%) | 4 (14.3%) | |
| Chondrosarcoma | 5 (10.9%) | 0 (0.0%) | 5 (17.9%) | |
| Othersa | 4 (8.7%) | 2 (11.1%) | 2 (7.1%) | |
| Adjuvant chemotherapy | 35 (76.1%) | 16 (88.9%) | 19 (67.9%) | 0.160 |
| Adjuvant radiotherapy | 4 (8.7%) | 2 (11.1%) | 2 (7.1%) | 0.639 |
| Irradiated | 14 (30.4%) | 2 (11.1%) | 12 (42.9%) | |
| Fresh-frozen | 32 (69.6%) | 16 (88.9%) | 16 (57.1%) | |
| Nail | 12 (26.1%) | 9 (50.0%) | 3 (10.7%) | |
| Bridging plate | 17 (37.0%) | 9 (50.0%) | 8 (28.6%) | |
| Nail + plate | 17 (37.0%) | 0 (0.0%) | 17 (60.7%) | |
aIn the VFG group: one fibrosarcoma, one undifferentiated carcinoma; in the no VFG group: one clear cell renal carcinoma, one haemangioendothelioma
Description of the population based on the postoperative follow-up data and comparison of the qualitative data between the VFG+ and VFG− subgroups using the chi2 or Fisher’s exact test and the quantitative data using the t-test
| Cohort, | VFG+, | VFG−, | ||
|---|---|---|---|---|
| 0.116 | ||||
| | 19 (41.3%) | 10 (55.6%) | 9 (32.1%) | |
| | 15 (32.6%) | 5 (27.8%) | 10 (35.8%) | |
| | 12 (26.1%) | 3 (16.6%) | 9 (32.1%) | |
| 1, excellent; 2, good | 39 (84.8%) | 18 (100%) | 21 (75.0%) | |
| 3, fair; 4, poor | 7 (15.2%) | 0 (0.0%) | 7 (25.0%) | |
| Henderson 1 | 1 (2.2%) | 1 (5.6%) | 0 (0.0%) | 0.391 |
| Henderson 2 | 17 (37.0%) | 6 (33.3%) | 11 (39.3%) | 0.683 |
| Henderson 3 | 9 (19.6%) | 2 (11.1%) | 7 (25%) | 0.448 |
| Henderson 4 | 3 (6.5%) | 1 (5.6%) | 2 (7.1%) | 1 |
| Allograft removala | 2 (4.3%) | 1 (5.6%) | 1 (3.6%) | 1 |
| Healed at last follow-up | 43 (93.5%) | 17 (94.4%) | 26 (92.9%) | 1 |
| Healed with no revision | 28 (60.9%) | 12 (66.7%) | 16 (57.1%) | 0.578 |
| Mean bone union delay (months) | 21.8 (4–120) | 12.6 (5–34) | 27.9 (5–120) | |
| MSTS (/30) ( | 27.3 (18–30) | 26.3 (21–30) | 28 (18–30) | 0.060 |
aExcluding oncological causes
Fig. 3Kaplan-Meier cumulative probability curves. A Kaplan-Meier cumulative probability curves for allograft bone union in the overall cohort and log-rank comparison of the VFG+ and VFG− groups. Complete follow-up and follow-up excluding revisions in the first 2 years. The estimated median time for the bone union was 12.0 months (95% CI, 7.8 to 16.2) for the VFG+ group vs. 20.0 months (95% CI, 14.8 to 25.2) for the VFG− group. B Kaplan-Meier survival curves with failure defined as allograft revision for the VFG+ and VFG− groups, excluding carcinologic causes. Excluding revisions in the first 2 years: global and comparative follow-up
Fig. 4Box-and-whisker plots for the MSTS scores in allograft reconstruction and subgroup analysis for the VFG+ and VFG− groups; outliers are shown as a dot or asterisk, Student’s t-test
Univariate and multivariate (stepwise forward conditional method) Cox model regression for allograft bone union and revisions after 2 years of follow-up
| Bone union, HRa (95.0% CI) | > 2 years revisions, HRa (95.0% CI) | |||
|---|---|---|---|---|
| Gender (male) | 1.06 (0.56–1.99) | 0.860 | 1.29 (0.38–4.32) | 0.672 |
| Age (years)b | 0.99 (0.96–1.02) | 0.460 | 1.01 (0.9–1.05) | 0.790 |
| Resection length (mm)b | 1.00 (0.94–1.06) | 0.967 | 0.98 (0.87–1.10) | 0.705 |
| Irradiated allograft | 0.68 (0.35–1.32) | 0.256 | ||
| Adjuvant radiotherapy | 0.32 (0.09–1.05) | 0.061 | 2.63 (0.72–9.71) | 0.144 |
| Adjuvant chemotherapy | 1.05 (0.51–2.14) | 0.894 | 1.10 (0.33–4.55) | 0.759 |
| Diagnosisc | ||||
| CHS (cref.) | 0.841 | 0.661 | ||
| OS | 0.75 (0.28–1.98) | 0.556 | 0.48 (0.14–1.67) | 0.251 |
| Ewing’s | 0.84 (0.29–2.43) | 0.742 | 1.20 (0.14–11.11) | 0.866 |
| Associated graft | ||||
| VFG−: | ||||
| | 1.98 (0.85–4.49) | 0.112 | 0.25 (0.03–2.00) | 0.192 |
| VFG+ | ||||
| Stabilisation | ||||
| Nail (cref.) | 0.149 | 0.095 | ||
| Plate | 1.17 (0.54–2.51) | 0.690 | 0.79 (0.13–4.98) | 0.814 |
| Nail + plate | 0.59 (0.27–1.30) | 0.191 | 3.38 (0.83–12.82) | 0.090 |
| Model | Model | |||
| Adjuvant RT | ||||
| Irradiated allograft | ||||
| Associated graft: VFG−: | ||||
| | 1.89 (0.80–4.44) | 0.145 | ||
| VFG+ | ||||
aHazard ratio. bContinuous variable. cReference variable in a categorical variable ≥ 3 levels
Fig. 5Intercalary femoral reconstruction for a high-grade fracture osteosarcoma using an allograft associated with a vascularised fibula graft and an LCP bridging plate. A Pre-operative pangonogram X-ray view. B Two-year follow-up X-ray view